CHINARES PHARMA (03320): China Resources Sanjiu Medical & Pharmaceutical's net profit attributable to shareholders in 2025 is approximately 3.422 billion yuan, an increase of 1.6% year-on-year.

CHINARES PHARMA (03320) announced that China Resources Sanjiu Medical & Pharmaceutical's performance in 2025, with total revenue of approximately 31.629 billion yuan, a year-on-year growth of 14.53%; the net profit attributable to shareholders of the listed company is approximately 3.422 billion yuan, a year-on-year growth of 1.6%; basic earnings per share is 2.06 yuan. In 2025, facing factors such as a decrease in the incidence of respiratory diseases such as the flu and continued control of medical insurance costs, China Resources Sanjiu Medical & Pharmaceutical is anchoring its strategic direction, adhering to the dual drive of "innovation + brand", and steadily advancing in a complex market environment. China Resources Sanjiu Medical & Pharmaceutical focuses on core treatment areas, expands the research and development pipeline in multiple dimensions, and explores innovative value. China Resources Sanjiu Medical & Pharmaceutical also enhances its brand advantage, continuously optimizes its business layout, forges a competitive advantage across the entire industry chain, consolidates its leading position in the industry, and solidly advances towards the strategic goal of "becoming a leading company in the industry."